



Jayex Technology Limited

(Formerly known as Jayex Healthcare Limited)

ABN 15 119 122 477

**APPENDIX 4E PRELIMINARY FINAL REPORT
31 December 2021**

PROVIDED TO THE ASX UNDER LISTING RULE 4.3A

For personal use only

Jayex Technology Limited
(Formerly known as Jayex Healthcare Limited)
Appendix 4E
Preliminary final report

1. Company details

Name of entity: Jayex Technology Limited
ABN: 15 119 122 477
Reporting period: For the year ended 31 December 2021
Previous period: For the year ended 31 December 2020

2. Results for announcement to the market

			\$'000
Revenues from ordinary activities (continuing and discontinued operations)	down	32.0% to	4,125
Loss from ordinary activities after tax attributable to the owners of Jayex Technology Limited	up	366.1% to	(3,724)
Loss for the year attributable to the owners of Jayex Technology Limited	up	366.1% to	(3,724)

Dividends

There were no dividends paid, recommended or declared during the current financial period.

Comments

The loss for the consolidated entity after providing for income tax amounted to \$3,724,000 (31 December 2020: \$799,000).

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	<u>(1.62)</u>	<u>(2.92)</u>

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous period

There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):


This report, and the accompanying summary consolidated financial statements, are based upon accounts which are in the process of being audited.

11. Attachments

Details of attachments (if any):

Unaudited summary consolidated financial statements for Jayex Healthcare Limited and its controlled entities for the period ended 31 December 2021 are attached.

12. Signed

Signed  _____

Date: 28 February 2022

For persons

Jayex Technology Limited
(Formerly known as Jayex Healthcare Limited)
Consolidated statement of profit or loss and other comprehensive income
For the year ended 31 December 2021

	Note	Consolidated 2021 \$'000	2020 \$'000
Revenue		3,586	5,069
Other income		251	545
Expenses			
Raw materials and consumables used		(571)	(1,091)
Employee benefits expense		(3,048)	(3,151)
Depreciation and amortisation expense		(606)	(854)
Marketing expenses		(107)	(90)
Administrative, corporate and other expenses		(1,542)	(1,498)
Finance costs		(841)	(380)
Net foreign exchange gains		154	106
Impairment of intangible assets		(2,514)	-
Fair value change in the derivative instrument		1,038	246
Loss before income tax benefit from continuing operations		(4,200)	(1,098)
Income tax benefit		379	142
Loss after income tax benefit from continuing operations		(3,821)	(956)
Profit after income tax expense from discontinued operations		97	157
Loss after income tax (expense)/benefit for the year attributable to the owners of Jayex Technology Limited		(3,724)	(799)
Other comprehensive income/(loss)			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Gain on the revaluation of financial assets at fair value through other comprehensive income, net of tax		57	-
Foreign currency translation		510	(659)
Other comprehensive income/(loss) for the year, net of tax		567	(659)
Total comprehensive loss for the year attributable to the owners of Jayex Technology Limited		<u>(3,157)</u>	<u>(1,458)</u>
Total comprehensive loss for the year is attributable to:			
Continuing operations		(3,254)	(1,458)
Discontinued operations		97	-
		<u>(3,157)</u>	<u>(1,458)</u>

Jayex Technology Limited
(Formerly known as Jayex Healthcare Limited)
Consolidated statement of profit or loss and other comprehensive income
For the year ended 31 December 2021

	Cents	Cents
Earnings per share for loss from continuing operations attributable to the owners of Jayex Technology Limited		
Basic earnings per share	(1.7)	(0.5)
Diluted earnings per share	(1.7)	(0.5)
Earnings per share for profit from discontinued operations attributable to the owners of Jayex Technology Limited		
Basic earnings per share	-	0.1
Diluted earnings per share	-	0.1
Earnings per share for loss attributable to the owners of Jayex Technology Limited		
Basic earnings per share	(1.7)	(0.4)
Diluted earnings per share	(1.7)	(0.4)

Jayex Technology Limited
(Formerly known as Jayex Healthcare Limited)
Consolidated statement of financial position
As at 31 December 2021

	Consolidated	
	2021	2020
	\$'000	\$'000
Assets		
Current assets		
Cash and cash equivalents	983	1,182
Trade and other receivables	839	1,173
Inventories	247	341
Other	48	56
Total current assets	<u>2,117</u>	<u>2,752</u>
Non-current assets		
Deposits	54	53
Investments	1,905	-
Plant and equipment	209	185
Right-of-use assets	247	132
Intangibles	5,545	9,237
Total non-current assets	<u>7,960</u>	<u>9,607</u>
Total assets	<u>10,077</u>	<u>12,359</u>
Liabilities		
Current liabilities		
Trade and other payables	1,034	1,992
Borrowings	2,607	2,961
Lease liabilities	150	98
Income tax	199	-
Employee benefits	50	54
Provisions	215	220
Contract liabilities	1,615	1,436
Total current liabilities	<u>5,870</u>	<u>6,761</u>
Non-current liabilities		
Borrowings	2,455	1,716
Lease liabilities	113	23
Deferred tax	139	461
Employee benefits	17	21
Total non-current liabilities	<u>2,724</u>	<u>2,221</u>
Total liabilities	<u>8,594</u>	<u>8,982</u>
Net assets	<u>1,483</u>	<u>3,377</u>
Equity		
Issued capital	28,112	26,861
Reserves	(1,549)	(2,128)
Accumulated losses	(25,080)	(21,356)
Total equity	<u>1,483</u>	<u>3,377</u>

Jayex Technology Limited
(Formerly known as Jayex Healthcare Limited)
Consolidated statement of changes in equity
For the year ended 31 December 2021

Consolidated	Issued capital \$'000	Shared-based payment reserve \$'000	Foreign exchange reserve \$'000	Asset revaluation reserve \$'000	Accumulated losses \$'000	Total equity \$'000
Balance at 1 January 2020	26,166	21	(1,469)	-	(20,557)	4,161
Loss after income tax benefit for the year	-	-	-	-	(799)	(799)
Other comprehensive loss for the year, net of tax	-	-	(659)	-	-	(659)
Total comprehensive loss for the year	-	-	(659)	-	(799)	(1,458)
<i>Transactions with owners in their capacity as owners:</i>						
Contributions of equity, net of transaction costs	674	-	-	-	-	674
Exercise of options	21	(21)	-	-	-	-
Balance at 31 December 2020	<u>26,861</u>	<u>-</u>	<u>(2,128)</u>	<u>-</u>	<u>(21,356)</u>	<u>3,377</u>

Consolidated	Issued capital \$'000	Shared-based payment reserve \$'000	Foreign exchange reserve \$'000	Asset revaluation reserve \$'000	Accumulated losses \$'000	Total equity \$'000
Balance at 1 January 2021	26,861	-	(2,128)	-	(21,356)	3,377
Loss after income tax benefit for the year	-	-	-	-	(3,724)	(3,724)
Other comprehensive income for the year, net of tax	-	-	510	57	-	567
Total comprehensive income/(loss) for the year	-	-	510	57	(3,724)	(3,157)
<i>Transactions with owners in their capacity as owners:</i>						
Contributions of equity, net of transaction costs	1,251	-	-	-	-	1,251
Share based payments	-	12	-	-	-	12
Balance at 31 December 2021	<u>28,112</u>	<u>12</u>	<u>(1,618)</u>	<u>57</u>	<u>(25,080)</u>	<u>1,483</u>

Jayex Technology Limited
(Formerly known as Jayex Healthcare Limited)
Consolidated statement of cash flows
For the year ended 31 December 2021

	Consolidated	
	2021	2020
	\$'000	\$'000
Cash flows from operating activities		
Receipts from customers (inclusive of GST)	3,879	6,809
Payments to suppliers and employees (inclusive of GST)	(5,373)	(7,187)
Operating activities from discontinued operations	210	157
	<u>(1,284)</u>	<u>(221)</u>
Other revenue	251	545
Interest and other finance costs paid	(224)	(507)
	<u>(1,257)</u>	<u>(183)</u>
Cash flows from investing activities		
Payments for plant and equipment	(44)	(1)
Payments for intangibles	(91)	(270)
Proceeds from disposal of Acute business	1,584	-
Payments for disposal of Acute business	(850)	-
Payment for investments	(1,369)	-
	<u>(770)</u>	<u>(271)</u>
Cash flows from financing activities		
Proceeds from issue of shares	1,292	700
Share issue transaction costs	(41)	(26)
Proceeds from borrowings	1,116	1,060
Repayment of borrowings	(112)	(200)
Repayment of convertible notes	(300)	-
Repayment of lease liabilities	(135)	(187)
	<u>1,820</u>	<u>1,347</u>
Net cash from financing activities		
Net increase/(decrease) in cash and cash equivalents	(207)	893
Cash and cash equivalents at the beginning of the financial year	1,182	281
Effects of exchange rate changes on cash and cash equivalents	8	8
	<u>983</u>	<u>1,182</u>
Cash and cash equivalents at the end of the financial year		